New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences Data showed ability of INO-3107 to induce an ...

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Immunotherapy, which enhances the immune system's T cell response to eliminate cancer cells, has emerged as a key approach in ...

Professor Heung Kyu Lee, KAIST Department of Biological Sciences, and Dr. Keun Bon Ku >Immunotherapy, which enhances the ...

Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen's leadership believes that ...

In the oral presentation, the investigators reported ongoing improved survival compared to historical controls, with 3 out of ...

Dr. Beata Halassy, a 49-year-old virologist, self-treated her recurrent breast cancer with OVT, a method that leverages ...

【导读】免疫检查点阻断（ICB）疗法已成为多种晚期癌症的新治疗范式，但由于低响应率，其广泛的临床应用受到了阻碍。在这项研究中，团队采用了一种基于肽的、仿生的、自组装策略，制造了一种纳米颗粒TPM1，用于结合肿瘤细胞表面的PD-L1。2024年11月9 ...

The three poster presentations included tumor microenvironment pharmacodynamic data from the phase 1/2 ARTISTRY ... Because ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

A Phase I study of invikafusp alfa presented at SITC provided the rationale to enroll patients with TMB-high, MSI-high, and virus-associated tumors in Phase II.